A Class in Session: Understanding Current and Future Therapeutic Advances Across B-Cell Lymphomas

Download All
In this comprehensive online program, experts discuss how to select optimal therapies for patients with B-cell lymphomas. Get up to date with expert commentaries, an on-demand webcast and slides from a dynamic CCO symposium at ASH 2021, downloadable resources on 10 key agent classes, and an audio podcast.
Julie M. Vose, MD, MBA
Program Director
Brad S. Kahl, MD
John P. Leonard, MD
Julie M. Vose, MD, MBA

On-Demand Webcast

In this on-demand webcast, Julie M. Vose, MD, MBA; Brad S. Kahl, MD; and John P. Leonard, MD, review the current treatment paradigm for B-cell lymphomas, including key updates from ASH 2021.

Julie M. Vose, MD, MBA
Program Director
Brad S. Kahl, MD John P. Leonard, MD
Physicians: maximum of 2.25 AMA PRA Category 1 Credits Released: February 7, 2022 Expired: February 6, 2023

ClinicalThought

Treatment options have grown increasingly complex for patients with follicular lymphoma. In this commentary, I share how I approach individualizing and sequencing therapy for patients with newly diagnosed and relapsed/refractory disease.

John P. Leonard, MD Released: November 1, 2021

How are you managing patients with mantle cell lymphoma? Read this commentary for my approach.

Brad S. Kahl, MD Released: November 12, 2021

Now that ibrutinib and zanubrutinib are both approved by the FDA in the relapsed/refractory setting for marginal zone lymphoma, where do we sequence and how do we choose between these BTK inhibitors? Read this commentary for my approach.

John P. Leonard, MD Released: November 2, 2021

How are you managing patients with diffuse large B-cell lymphoma? Read this commentary for my approach.

Julie M. Vose, MD, MBA Released: December 1, 2021

How are you managing patients with EBV-associated posttransplant lymphoproliferative disease? Read this commentary for my approach.

Julie M. Vose, MD, MBA Released: December 6, 2021

Downloadable Slidesets

Download this slideset from a live satellite symposium at ASH 2021 on current and emerging treatment options for patients with follicular lymphoma.

John P. Leonard, MD Released: December 15, 2021

Download this slideset from a live satellite symposium at ASH 2021 on current and emerging treatment options for patients with marginal zone lymphoma and mantle cell lymphoma.

Brad S. Kahl, MD Released: December 16, 2021

Download this slideset from a live satellite symposium at ASH 2021 on current and emerging treatment options for patients with marginal zone lymphoma and mantle cell lymphoma.

Julie M. Vose, MD, MBA Released: December 16, 2021

Download this slideset from a live satellite symposium at ASH 2021 on current and emerging treatment options for patients with EBV-associated post-transplant lymphoproliferative disorders.

Julie M. Vose, MD, MBA Released: December 16, 2021

Gain key clinical insights fast, with this short slideset from CCO on key considerations for optimal treatment of B-cell lymphomas.

Brad S. Kahl, MD John P. Leonard, MD Julie M. Vose, MD, MBA Released: January 4, 2022

Resources

Download this online resource developed to serve as a helpful guide for healthcare professionals on BCL-2 targeted therapies in B-cell lymphoma.

Released: December 10, 2021

Download this online resource developed to serve as a helpful guide for healthcare professionals on PI3K inhibitors in B-cell lymphoma.

Released: December 13, 2021

Download this online resource developed to serve as a helpful guide for healthcare professionals on CAR T-cell therapies in B-cell lymphoma.

Released: December 10, 2021

Download this online resource developed to serve as a helpful guide for healthcare professionals on epigenetic therapies in B-cell lymphoma.

Released: December 13, 2021

Download this online resource developed for healthcare professionals with a helpful guide for antibody-based therapies in B-cell lymphoma.

Released: December 17, 2021

Download this online resource developed to serve as a helpful guide for healthcare professionals on bispecific antibodies in B-cell lymphomas.

Released: December 27, 2021

Download this online resource developed to serve as a helpful guide for healthcare professionals on BTK inhibitors in B-cell lymphoma.

Released: January 4, 2022

Download this online resource developed to serve as a helpful guide for healthcare professionals on immunomodulatory agents and immune checkpoint inhibitors in B-cell lymphomas.

Released: December 27, 2021

Download this online resource developed to serve as a helpful guide for healthcare professionals on XPO1 and nuclear export inhibitors in B-cell lymphomas.

Released: December 28, 2021

Download this online resource developed to serve as a helpful guide for healthcare professionals on antibody–drug conjugates in B-cell lymphomas.

Released: December 29, 2021

Podcast

In this podcast episode, listen to Julie M. Vose, MD, MBA; Brad S. Kahl, MD; and John P. Leonard, MD, discuss current and emerging treatment approaches for patients with B-cell lymphomas from a recent satellite symposium at the annual Hematology meeting in 2021.

Brad S. Kahl, MD John P. Leonard, MD Julie M. Vose, MD, MBA Released: February 25, 2022

In these notes from a podcast, read expert insights from Julie M. Vose, MD, MBA; Brad S. Kahl, MD; and John P. Leonard, MD, on treatment options for patients with B-cell lymphomas from a recent symposium held during the annual Hematology meeting in 2021.

Julie M. Vose, MD, MBA
Program Director
Brad S. Kahl, MD John P. Leonard, MD
Released: February 25, 2022
Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
Atara Biotherapeutics, Inc.
Bayer HealthCare Pharmaceuticals Inc.
BeiGene, Ltd.
Epizyme
Genentech, a member of the Roche Group
Genmab US, Inc.
Incyte Corporation
Karyopharm Therapeutics
Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc.

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings